Nusinersen Shows Efficacy in Infantile- and Late-Onset Spinal Muscular Atrophy

The new data further cemented the therapy’s consistent safety profile from previous studies as well as demonstrated a newfound durability in patients with later-onset spinal muscular atrophy. 

Source link

Related posts

No Protective Effect of Moderate Drinking on Stroke Risk


Tissue metabolite profiles for the characterisation of paediatric cerebellar tumours


Polyneuropathy in Gaucher disease type 1 and 3 – a descriptive case series


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World